Blood Volume Bva 100 Diagnostic In The Evaluationnical Benefit Of Daxor S Blood Volume Bva 100 Diagnostic Articles & Analysis
65 news found
Medical Equipment Pump Solutions Industry Overview IVD, which stands for in vitro diagnostics, refers to products that conduct testing on samples taken from the human body (such as blood, body fluids, and tissues) outside of the body in order to obtain clinical diagnostic information. The IVD industry is subdivided into various sectors including immunodiagnostics, clinical chemistry, molecular ...
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant growth of blood volume analysis (BVA) ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. “Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to the Daxor team ...
In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma. The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond Young, would receive ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Americans ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic ...
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. In addition, the underwriter has partially exercised its over-allotment ...
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of an underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. The gross proceeds to Daxor from the offering, before deducting the underwriting commissions and ...
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Daxor. In addition, Daxor intends to grant the underwriter in the offering a 45-day option to ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be featured in a MedAxiom Academy webinar – Best Practices for Using Blood Volume Analysis to Reduce Heart Failure LOS, Readmissions, Mortality and Costs on November 17, 2022, at 1pm ET. This live webinar will take a deep dive into the best ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the prestigious Journal of Cardiac Failure demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF). The researchers showed that Daxor’s BVA-100 was able to measure intravascular volume overload in heart failure ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart Association Scientific Sessions (AHA) at McCormick Place Convention Center in Chicago, IL from November 5-7th, 2022. “The AHA Scientific Sessions is a leading event connecting over 15,000 experts from over one hundred countries focused on ...
The Premier Event for The Cardiovascular Industry’s Leading Network of Executives and Clinicians – Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and Patient-Care Outcomes Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting for the first time at the MedAxiom CV ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that a scientific session titled “Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure” was held during the Heart Failure Society of America Annual Scientific Meeting on October 3rd, 2022, in Washington, DC. In a debate format ...
Telehealth use skyrocketed in the early months of the Covid-19 pandemic when many health providers were forced to deliver services remotely. Although telehealth visits have dropped from their peak in 2020, they remain elevated even as many patients return to in-person care, according to the results of an analysis by Epic Research and the Kaiser Family Foundation. Survey results show that ...
Why should payers care about clinical laboratory testing? Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting – which brought together the world’s ...